Document is current
Any future updates will be listed below
-
Authors
Gulova, Slavomira https://orcid.org/0000-0001-8911-3199
Otahal, Alexander
Kramer, Karina
Rothammer, Markus
Lacza, Zsombor
Harvanova, Denisa
Nehrer, Stefan
De Luna, Andrea
-
Funding
Funding for this research was provided by:
Gesellschaft für Forschungsförderung Niederösterreich (LSC18-014)
Österreichische Agentur für Internationale Mobilität und Kooperation in Bildung, Wissenschaft und Forschung (SK11/2024)
Agentúra na Podporu Výskumu a Vývoja (SK-AT-23-0005)
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 15 September 2025
First Online: 24 October 2025
Declarations
:
: This study has been approved by the ethics committee of Karl Landsteiner Private University, Austria (EK 1020/2020) and was conducted in accordance with declaration of Helsinki. (1) Title of the approved project: Extracellular vesicles from Hoffa´s fat pad- a new strategy for cartilage regeneration. (2) Name of the institutional approval committee: The ethics committee of Karl Landsteiner Private University, Austria. (3) Approval number: EK 1020/2020. (4) Date of approval: 15/07/2020. Tissue samples were obtained from patients, following written informed consent for participation in the study and/or the use of samples. Whole blood samples were collected in-house from healthy volunteers, after informed consent, with approval from the ethics committee of the University for Continuing Education Krems, Austria. (1) Title of the approved project: Collection of human whole blood for scientific purposes. (2) Name of the institutional approval committee: The ethics committee of the University for Continuing Education Krems, Austria. (3) Approval number: EK GZ 13/2015–2018. (4) Date of approval: 14/01/2013 (confirmation of continuation 04/04/2022). The human THP-1 cell line ( #TIB-202 ™) used in this study was purchased from the American Type Culture Collection (ATCC). The original derivation of the THP-1 cell line was described by Tsuchiya et al. (1980, International Journal of Cancer) [ ], where the establishment from a human donor was reported. While ATCC does not explicitly state details of ethical approval and informed consent for this cell line on their website, by standard practices ATCC requires that human-derived materials meet ethical sourcing requirements. No additional ethical approval was required for this study. A standard Material Transfer Agreement (MTA) was accepted as part of the purchase process from ATCC.
: Not applicable.
: Zsombor Lacza is CEO of Orthosera GmbH, the other authors declare that they have no competing interests.
